Foeldvari Ivan
Hamburg Centre for Pediatric and Adolescent Rheumatology, Centre for Treatment of Scleroderma and Uveitis in Childhood and Adolescence, Teaching Unit of the Asklepios Campus of the Semmelweis Medical School, Budapest, An der Schön Klinik Hamburg Eilbek, Dehnhaide 120, 22081, Hamburg, Germany,
Curr Rheumatol Rep. 2015 Mar;17(3):18. doi: 10.1007/s11926-014-0491-y.
Juvenile systemic sclerosis is an orphan disease of the macro- and microvasculature with an unknown etiology. Although pediatric and adult classification systems have been developed, neither has been validated yet. Recent publications have shown a shift in the subset pattern in juvenile-onset adult patients, with a better outcome in these patients as compared with young adult patients. As a first step in assessing activity, damage, and severity, a pediatric severity score--a modification of the adult Medsger scale--was proposed but has not been validated. An activity score also has been developed but has not yet been published. Currently, treatment approaches are based only on adult data, and problems exist in extrapolating these data to a pediatric population.
青少年系统性硬化症是一种病因不明的大血管和微血管孤儿病。尽管已经制定了儿科和成人分类系统,但均尚未得到验证。最近的出版物显示,青少年发病的成年患者的亚型模式有所变化,与年轻成年患者相比,这些患者的预后更好。作为评估活动度、损伤和严重程度的第一步,有人提出了一种儿科严重程度评分——对成人梅兹格量表的修改版,但尚未得到验证。一种活动度评分也已制定,但尚未发表。目前,治疗方法仅基于成人数据,将这些数据外推至儿科人群存在问题。